| Biomarker ID | 1415 |
| PMID | 24741114 |
| Year | 2014 |
| Biomarker | TIMP1; CLUS; MFAP4; AOC3; CADM1; HYOU1; FSTL1; KLK11; NBL1; GOLM1; VTNC; CERU; A1AG2; LYVE1; A1AG1; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Metastatic PCa;Downregulated in Non Metastatic PCa: [] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Metastatic Vs Non Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 25 patients with Metastatic Prostate Cancer (PCa); 10 normal samples; 24 Non Agressive PCa patients and 16 agressive PCa patients were included in the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | SWATH Mass Spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |